Cognetivity Neurosciences (CSE: CGN) has seen the deployment of its technology to a new region globally. The firm revealed this morning the first commercial arrangement to deploy its tech within the middle east.
The agreement will see the deployment of the firms Integrated Cognitive Assessment at the Clemenceau Medical Center in Dubai, just weeks after its initial roll out in the region. Known as one of the leading hospitals in the region for a wide range of specialties, the CMC is located within the Dubai Healthcare City, and is said to be closely affiliated with the world-renowned Johns Hopkins Medicine International.
The deployment will see Cognetivity’s ICA used for the early detection of dementia and mild cognitive impairment. Given that the test is language-independent, it is well suited for global deployment in such scenarios.
“Dementia is a serious and growing healthcare problem all over the world, including the Middle East. The ICA offers hope as a cutting-edge technology that can drive great improvements in the quality and efficiency of cognitive assessment, particularly at the all-important earlier stages of disease,” commented Dr Raja Sawaya, a neurologist and clinical neurophysiologist whom will be overseeing the implementation of the tech at CMC.
Commercial terms of the arrangement were not provided.
Cognetivity Neurosciences last traded at $0.62 on the CSE.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
